Hormone Receptor Positive Breast Cancer

For me, I have restrained giving adjuvant chemotherapy to women over 60 with resected zero or few positive node breast cancer that was heavily ER positive. I thought Tamoxifen or AI was sufficient. Pretty much every other oncologist in town gave chemotherapy. Seemed excessive. (@davideyoungmd)

WATCH: @YAbdouMD, of @UNC_Lineberger, discusses updates in the treatment of patients with HR-positive, HER2-negative breast cancer. #bcsm #oncology https://t.co/bm3XbNunzN (@OncLive)

Continued research efforts have solidified the use of targeted therapies in HR-positive breast cancer and indicate the importance of further research with HER3-directed ADCs in metastatic disease. @maryam_lustberg @SmilowCancer @ASCO #ASCO23 #bcsm https://t.co/dJIGDZReL7 (@OncLive)

🎥@MichaelGnant of @MedUni_Wien discusses late recurrences in ER-positive breast cancer at #ASCO23. Optimal treatment duration is 7-8 years, with 10 years for high-risk cases. The carryover effect brings long-lasting benefits: ➡️https://t.co/OG8RHYWG95⬅️ #BreastCancer #BCSM (@VJOncology)

Excellent panel discussion for Session IV on ER Positive Breast Cancer in the #HarvardBreastCancerCourse. #PabloLeone @PTarantinoMD @elmayermd @alex_toker @christinaminami @RMJesel @BeverlyMoy @drsarahsam (@DFCI_BreastOnc)

Sarah Sammons, MD, discusses the evolving role of CDK4/6 inhibitors in HR-positive breast cancer, the future of ADCs in TNBC, and the importance of a shared decision-making process in breast cancer treatment. @drsarahsam @DanaFarber #bcsm #oncology https://t.co/eAR3QZt7Pa (@OncLive)

If you're looking for a quick overview of the latest advances in ER+ breast cancer treatment options, check out this money slide! It captures all the recent updates in one glance @AkshjotP @bmtdoc63 @binayshah @OncoAlert @btfoundation #breastcancer #ERpositive #cancerresearch https://t.co/el9xNm5Bng (@VivekSubbiah)

@ASCO Educational Book provides insightful summaries with great impact on clinical practice! @ABCSGVienna President @MichaelGnant contributes with an overview – based on his ASCO talk – on managing ER-positive breast cancer and challenges of late relapse. https://t.co/mwD3euw9w2 (@ABCSGVienna)

I went through menopause 15 years ago, gp’s only support was to give me Prozac, I had to find my own help. There are so many products out there, some affecting hormones, feels so dangerous! diagnosed with oestrogen positive breast cancer 2020, I question safety of products (@cardiffsian)

🏆 Huge congrats to my friend @Lucarecco from @UniGenova @SanMartino_Ge on an outstanding presentation at #ESHRE2023! Proud to be a co-author of this important work, confirming the safety of #pregnancy after hormone receptor-positive #BreastCancer diagnosis. @OncoAlert 🥇🚀 (@boutrosand)

New📰published: AMEERA-3: Randomized Phase II Study of Amcenestrant Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. @stolaney1 and colleagues. https://t.co/QqL6DtT4C7 (@DFCI_BreastOnc)

You give me so much strength, so often. Usually I'm one of your MANY silent followers. But now you need support. What you say, what you teach is wonderful. I had hormone positive breast cancer. So far I'm ok, and you help so often with your wonderful knowledge. THANK YOU😁 (@SarahSallyRobe1)

Yes if you have estrogen positive breast cancer. (@lauracallaway20)

all the metastatic hormone positive her2 negative breast cancers don’t benefit from CDK4/6 inhibitors in front line! Speaker: Barbara Pistilli #florencebreast23 @OncoAlert @acampsmalea @ChelainG @MartaPerachino @FatjonaKrajaMD @FrancicaPaola (@Dr_m_garousi)

WATCH: @stolaney1, of @DanaFarber, discusses key data from a final overall survival analysis of the phase 3 TROPiCS-02 trial in hormone receptor–positive, HER2-negative breast cancer. #bcsm https://t.co/aFwiSRwpDr (@OncLive)

Check out Dr. Michail Ignatiadis @MIgnatiadis @JulesBordet discussing #ASCO23 Primary Efficacy Analyses of NeoRHEA, #Neoadjuvant #Biomarker Research Study of Palbociclib w/Endocrine Therapy in Estrogen Receptor Positive/HER2- BC #bcsm #breastcancer @EORTC https://t.co/iwysbmWmEj (@Sameh_VuMedi)

Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). @stolaney1 Summary: https://t.co/EhtJ4vYzX0 #ASCO23 #bcsm (@paspears88)

Breast Cancer Research: Final results of TROPiCS-02 reported at #ASCO23. Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer Read more ➡️ https://t.co/mBMz5ZnZox CC: @DFCI_BreastOnc @STolaney1 (@DanaFarberNews)

Prof Carlo Palmieri @cancermedic from @CCCNHS who with Prof Charles Coombes @imperialcollege co-authored our #ASCO23 poster outlining validation of @digistain novel approach to predicting outcomes in adjuvant therapy decision making for hormone receptor-positive #breastcancer (@digistain)

Impact of #HER2LOW expression in the #Oncotype DX RS in patients with operable hormone receptor positive early-stage #breastcancer @LauraSofiaMuno9 @MCristofanill @ASCO #ASCO23 (@CtcLaboratory)

Circulating tumor cells (#CTCs) dynamics after CDK4/6i for hormone receptor positive (HR+) #metastaticbreastcancer (MBC): a biomarker analysis of the PACE randomized phase II study @LGerratana @MCristofanill @CroAviano @WCM_MeyerCancer @DFCI_BreastOnc (@CtcLaboratory)

In this video, Adam Brufsky, MD, PhD, FACP, discusses palbociclib as a treatment option for patients with ER-positive, HER2-negative, advanced breast cancer. #bcsm | @UPMCHillmanCC @breastoncdoc @UPMCnews https://t.co/hl2rtyvCfz (@TargetedOnc)

Presented at #ASCO23 very important data from the #SOFT trial to increase our understanding of the biology of hormone receptor-positive/HER2-negative #BreastCancer in premenopausal women: congratulations @LoiSher @etop_ibcsg et all! @OncoAlert (@matteolambe)

Not to miss at #ASCO23: Today: Education Session Hall D1: Managing a Long and Winding Road: ER-Positive Breast Cancer Hear @MichaelGnant Editor-in-Chief of Breast Care, speak on Late Recurrences in ER-Positive Breast Cancer: What Else Can We Do? #BreastCancer @KargerPublisher (@OncoKarger)

The addition of ribociclib to endocrine therapy extended invasive DFS for patients with hormone receptor-positive, HER2-negative early-stage breast cancer #ASCO23 @UCLAJCCC @MDAndersonNews @NovartisCancer @DrDebuTripathy #Kisqali #NATALEE https://t.co/je2JJdsf0t (@HemOncToday)

Lerociclib/Fulvestrant May Reduce Risk of Disease Progression in Advanced HR-Positive/HER2-Negative Breast Cancer https://t.co/TWzsHInxAr @ASCO #ASCO23 @glopesMD (@GlopesMd)

@ASCO Abstract # 575 'Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer.' #ASCO23 @LauraSofiaMuno9 @eleonora_nicolo @eleniandreop @JeannineDonahue @MCristofanill @LANewmanMD @CiglerTessa (@CtcLaboratory)

SCI member Allison Kurian & others found screening for risk-reducing medication could decrease the risk of #BreastCancer death. https://t.co/LSP2ypKHDu @AllisonKurian #ERpositive (@SCIDirector)

In metastatic breast cancer treated with targeted therapy and endocrine therapy, new research shows no difference in survival between patients with HR positive disease with low HER2 vs. those with no HER2 expression https://t.co/lqEwgZXAf3 @ASCOPost @JAMouabbi #EndCancer (@MDAndersonNews)

Adding #NATALEE trial to the list, Adj Ribo for high risk HR+ breast cancer patients, Ph III (thank you, @PTarantinoMD for bringing this up) #bcsm #breastcancer (@OncBrothers)

In this video, Asst. Prof. @DrSGraff discusses current and planned investigations of the emerging antibody-drug conjugate datopotamab deruxtecan in patients with metastatic hormone receptor–positive #BreastCancer and triple-negative breast cancer. Watch: https://t.co/CpiltA24Fh (@BrownMedicine)

The TOT-HER3 study investigated HER3-DXd in previously untreated HR+positive/HER2- tumors early breast cancer in cohorts with different ERBB3 mRNA expression levels. Change in CelTIL score was the primary endpoint https://t.co/6Py1TBx9sv @_SOLTI @MOliveira_MD @prat_aleix #bcsm (@Annals_Oncology)

Adjuvant treatment decisions among adults aged 65 years and older with early-stage hormone receptor positive breast cancer seen in a simple multidisciplinary clinic versus standard consultation https://t.co/wl0SGRRYmP @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults (@JGeriOnc)

#ASCO Guideline Update on Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer from @DrHBurstein et al #bcsm #MBC #breastcancer (@DFCI_BreastOnc)

SABCS 2017: Circulating Tumor Cells May Predict Late Recurrence in Patients With Hormone Receptor–Positive Breast Cancer [12/8/17] @ASCOPost https://t.co/1A14bpi1Qg #bcsm #caprev #cactc (@mtmdphd)

Guideline Update Provides New Testing & Tx Recx for Pts w/ ER-Positive, HER2-Negative Met Breast Cancer w/ ESR1 Mutations [May 17-18, 2023] @ASCO Daily News - https://t.co/3ZVrEkQEN5 @DrHBurstein et al. @JCO_ASCO https://t.co/68e7D0CSgU #bcsm #PrecisionMedicine #LiquidBiopsy (@mtmdphd)

Check out the Society's Newly Revised Resource Guide to Endocrine Management of Hormone Receptor Positive Breast Cancer. @SBoolbol @AnjaliThawaniMD @DrJudyBoughey https://t.co/wEKWUEkrMH (@ASBrS)

1/4 Happy to share our newly published @MDAndersonNews paper where we investigated whether #HER2low status is a prognostic factor in #metastatic hormone receptor positive #breastcancer #bcsm https://t.co/plvHqwYo3t (@JAMouabbi)

Adjuvant abemaciclib should not be prescribed to women with high-risk, oestrogen-receptor positive breast cancer. Lancet Oncol 2023 - Published Online, May 2, 2023 https://t.co/tlMyjFON4t (@RCaponero)

@ASCO #ASCO23 #ASCODailyNews ER-Positive Breast Cancer: Assessing Late Relapse and Moving Treatment Forward https://t.co/0vIqH2EzGs (@GlopesMd)

Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor-Positive Breast… https://t.co/ldv8nKQjkM Very nice paper! Congrats to French colleagues for shedding lights on recurrence vs second primary BC! (@FilippoMontemu1)

Watch Dr. Jennifer Litton discuss treatment recommendations and supporting research on use of endocrine therapy and CDK4/6 inhibitors for both metastatic and high-risk, early HR positive/HER2 negative breast cancer. https://t.co/b2WPpFRNbp @MDEdgeTweets @JenniferLitton #EndCancer (@MDAndersonNews)